Folker Wenzel
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Folker Wenzel has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
Günther Giers
From the Institute for Transplantation Diagnostics and Cell Therapy, University of Duesseldorf, Duesseldorf, Germany; Blood Donation Service Munich, Germany; Hospital Laboratory Network Brandenburg‐Berlin, Germany; Institute of Haemostaseology and Transfusion Medicine, University of Duesseldorf; Frauenklinik Inselspital Bern University Hospital; and Medical Faculty Heinrich Heine University Duesseldorf, Duesseldorf, Germany
2 shared publicationsBoris Tutschek
From the Institute for Transplantation Diagnostics and Cell Therapy, University of Duesseldorf, Duesseldorf, Germany; Blood Donation Service Munich, Germany; Hospital Laboratory Network Brandenburg‐Berlin, Germany; Institute of Haemostaseology and Transfusion Medicine, University of Duesseldorf; Frauenklinik Inselspital Bern University Hospital; and Medical Faculty Heinrich Heine University Duesseldorf, Duesseldorf, Germany
1 shared publicationErnst M. Quenzel
From the Institute for Transplantation Diagnostics and Cell Therapy, University of Duesseldorf, Duesseldorf, Germany; Blood Donation Service Munich, Germany; Hospital Laboratory Network Brandenburg‐Berlin, Germany; Institute of Haemostaseology and Transfusion Medicine, University of Duesseldorf; Frauenklinik Inselspital Bern University Hospital; and Medical Faculty Heinrich Heine University Duesseldorf, Duesseldorf, Germany
1 shared publication- Johannes Christian Fischer
Institute for Transplantation Diagnostics and Cellular Therapeutics Heinrich Heine University Düsseldorf Düsseldorf Germany
1 shared publication - Rainer Moog
Octapharma Plasma GmbH, Langenfeld, Germany
1 shared publication Regina Riethmacher
From the Institute for Transplantation Diagnostics and Cell Therapy, University of Duesseldorf, Duesseldorf, Germany; Blood Donation Service Munich, Germany; Hospital Laboratory Network Brandenburg‐Berlin, Germany; Institute of Haemostaseology and Transfusion Medicine, University of Duesseldorf; Frauenklinik Inselspital Bern University Hospital; and Medical Faculty Heinrich Heine University Duesseldorf, Duesseldorf, Germany
1 shared publication
Latest Publications
- 7 January 2011
- Published by Wiley in Transfusion
- Vol. 51 (7) , 1431-1438
Reducing costs in flow-cytometric counting of residual white blood cells in blood products: utilization of a single-platform bead-free flow-rate calibration method
Commercial flow-cytometric methods for counting residual white blood cells (rWBCs) in leukoreduced blood products use calibration beads for estimation of the measured sample volume. A bead-free flow-rate calibration method is developed and validated. The analyzed volume was calculated by acquisition time (ACQ). Twenty-nine spiking series of red blood cell (RBC) or platelet (PLT) products were prepared containing levels ranging from 0.08 × 10(6) up to 2048 × 10(6) WBCs/L. Nearly WBC-free triple-leukofiltered RBCs or PLT concentrates (PCs) served as background. Propidium iodide (PI) was used to identify rWBCs. Five RBC series were compared against a commercially available kit (LeukoSure, Beckman Coulter). Routine capabilities were tested on 41 RBC and 92 PC samples of two independent transfusion services. The lower detection limit in RBC was 0.08 × 10(6) rWBCs/L for ACQ and 0.16 for LeukoSure. Criteria for linearity, accuracy, and precision were fulfilled within the range of 0.5 × 10(6) to 512 × 10(6) WBCs/L. For PCs, all these criteria were fulfilled between 0.5 × 10(6) and 32 × 10(6) rWBCs/L (lower detection limit of 0.25) for PI. ACQ and LeukoSure agreed sufficiently (81%) when tested on routine RBCs or PCs. A residual WBC count of fewer than 0.5 × 10(6) WBCs/L can be accurately counted using the ACQ approach at a total reagent cost of less than 0.5€ per sample.
- 7 January 2011
- Published by Wiley in Transfusion
- Vol. 51 (7) , 1431-1438
Reducing costs in flow-cytometric counting of residual white blood cells in blood products: utilization of a single-platform bead-free flow-rate calibration method
Commercial flow-cytometric methods for counting residual white blood cells (rWBCs) in leukoreduced blood products use calibration beads for estimation of the measured sample volume. A bead-free flow-rate calibration method is developed and validated. The analyzed volume was calculated by acquisition time (ACQ). Twenty-nine spiking series of red blood cell (RBC) or platelet (PLT) products were prepared containing levels ranging from 0.08 × 10(6) up to 2048 × 10(6) WBCs/L. Nearly WBC-free triple-leukofiltered RBCs or PLT concentrates (PCs) served as background. Propidium iodide (PI) was used to identify rWBCs. Five RBC series were compared against a commercially available kit (LeukoSure, Beckman Coulter). Routine capabilities were tested on 41 RBC and 92 PC samples of two independent transfusion services. The lower detection limit in RBC was 0.08 × 10(6) rWBCs/L for ACQ and 0.16 for LeukoSure. Criteria for linearity, accuracy, and precision were fulfilled within the range of 0.5 × 10(6) to 512 × 10(6) WBCs/L. For PCs, all these criteria were fulfilled between 0.5 × 10(6) and 32 × 10(6) rWBCs/L (lower detection limit of 0.25) for PI. ACQ and LeukoSure agreed sufficiently (81%) when tested on routine RBCs or PCs. A residual WBC count of fewer than 0.5 × 10(6) WBCs/L can be accurately counted using the ACQ approach at a total reagent cost of less than 0.5€ per sample.
- 1 January 2010
- Published by SAGE Publications in Clinical Hemorheology and Microcirculation
- Vol. 44 (2) , 137-144
Alteration of serum thrombopoietin levels in patients with chronic hepatitis C under interferon therapy
Thrombocytopenia is commonly observed during interferon-α (IFN-α) therapy in patients with chronic hepatitis C. Since thrombopoietin (TPO) is the main regulator of thrombopoiesis, thrombocytopenia may partially be due to a reduced TPO generation. Because of the developments of the second generation of TPO mimetic drugs patients with reduced TPO levels should be identified possibly having a benefit by medicinal stimulation of thrombopoiesis. Therefore, platelet count and serum TPO concentration of patients receiving an interferon-α therapy were determined. Twelve patients treated with IFN-α (daily 10×106 IU s.c. for four weeks) in cause of chronic hepatitis C were examined during the first month of therapy. Serum TPO concentration significantly decreased from 80.8±48.0 to 34.6±24.5 pg/ml (p<0.05, Mann–Whitney test), and platelet count declined from 214,417±48,292 to 151,333±44,726 platelets/μl. During the following three weeks platelet count remained at a low level, while serum TPO increased to normal range. In conclusion, an interferon treatment causes reduced serum TPO level during the first week of therapy accompanied by decreased platelet count. The reduction in TPO synthesis contributes to the development of thrombocytopenia in patients during interferon therapy.
- 1 January 2010
- Published by SAGE Publications in Clinical Hemorheology and Microcirculation
- Vol. 44 (2) , 137-144
Alteration of serum thrombopoietin levels in patients with chronic hepatitis C under interferon therapy
Thrombocytopenia is commonly observed during interferon-α (IFN-α) therapy in patients with chronic hepatitis C. Since thrombopoietin (TPO) is the main regulator of thrombopoiesis, thrombocytopenia may partially be due to a reduced TPO generation. Because of the developments of the second generation of TPO mimetic drugs patients with reduced TPO levels should be identified possibly having a benefit by medicinal stimulation of thrombopoiesis. Therefore, platelet count and serum TPO concentration of patients receiving an interferon-α therapy were determined. Twelve patients treated with IFN-α (daily 10×106 IU s.c. for four weeks) in cause of chronic hepatitis C were examined during the first month of therapy. Serum TPO concentration significantly decreased from 80.8±48.0 to 34.6±24.5 pg/ml (p<0.05, Mann–Whitney test), and platelet count declined from 214,417±48,292 to 151,333±44,726 platelets/μl. During the following three weeks platelet count remained at a low level, while serum TPO increased to normal range. In conclusion, an interferon treatment causes reduced serum TPO level during the first week of therapy accompanied by decreased platelet count. The reduction in TPO synthesis contributes to the development of thrombocytopenia in patients during interferon therapy.